Media Contact:
Stephen Majors
Vice President, Global Communications
smajors@alliancerm.org
Washington, DC
Three leading organizations that represent the scientists, academic centers, biotechnology organizations, patients, and service providers closest to the cell and gene therapy field today called for a ten-year global moratorium on heritable human genome editing (HHGE).
Washington, DC
Dr. Peter Marks has been a visionary leader, advocate for rare disease patients, and champion of cell and gene therapy (CGT) during his nine-year tenure as the Director of FDA’s Center for Biologics Evaluation and Research. He made many significant contributions to the field over the years and will be missed.
Phoenix, AZ
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2025 Board of Directors.
Brussels, BE
The new EU Joint Clinical Assessment (JCA) will become an additional barrier for patient access to transformative advanced therapies if the HTA Coordination Group does not modernize its approach to evaluating these medicines, warned 30 not-for-profit organisations, including patient groups, scientific societies, research foundations and medical institutes, in a Call to Action.
